ACCESSWIRE
15 Nov 2019, 18:13 GMT+10
HENNIGSDORF, GERMANY / ACCESSWIRE / November 15, 2019 / SphingoTec GmbH ('sphingotec') today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in Düsseldorf, Germany. To improve the management of critically ill patients in acute care settings through timely diagnostic, sphingotec has started making available novel biomarkers that complement a broad menu of existing standard of care tests on its Nexus IB10 point-of-care platform.
The Nexus IB10 point-of-care technology provides test results on whole blood sample in only 20 minutes and can be flexibly deployed in emergency departments, intensive care units, and any laboratory setting. In addition to the increasing menu of assays for proprietary biomarkers, the platform features a broad menu of 8 rapid tests for acute care settings including parameters such as the Troponin-I, NT-proBNP, and D-Dimer. Following the acquisition of Nexus Dx Inc., San Diego, USA, in 2018 from the Korean manufacturer Samsung, sphingotec markets the Nexus IB10 point-of-care platform through its continuously expanding distribution network.
Visit sphingotec at Medica 2019
sphingotec showcases its Nexus IB10 instrument and test portfolio as well as its proprietary biomarkers for acute care conditions at Medica 2019 and welcomes healthcare professionals as well as distributors and diagnostics and pharmaceutical industry representatives interested in partnering at its booth G52 in hall 3.
References
[1] Takagi et. al. (2019) Circulating dipeptidyl-peptidase 3 and alteration in hemodynamics in cardiogenic shock: Results from the OptimaCC Trial, European Journal of Heart Failure
[2] Deniau et. al. (2019) Circulating dipeptidyl peptidase-3 is a myocardial depressant factor: DPP3 inhibition rapidly and sustainably improves hemodynamics, European Journal of Heart Failure
[3] Siong Chan (2018) Proenkephalin in heart failure
[4] Hollinger et. al. (2018) Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Press Release Kidney in Sepsis and Septic Shock (Kid-SSS) Study
[5] Beunders et. al. (2017) Proenkephalin (PENK) as a novel biomarker for kidney function.
[6] Geven et. al. (2018) Geven 2018 Vascular effects of adrenomedullin and the anti-adrenomedullin antibody Adrecizumab in sepsis
[7] Mebazaa et. al. (2018) Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1
(AdrenOSS-1) study
[8] ter Maaten et. al.(2019) Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure
About sphingotec
SphingoTec GmbH ('sphingotec' Hennigsdorf by Berlin, Germany) develops and markets innovative in vitro diagnostic IVD tests for novel and proprietary biomarkers for the diagnosis, prediction and monitoring of acute medical conditions, such as acute heart failure, circulatory shock, and acute kidney injury in order to support patient management and provide guidance for treatment strategies. sphingotec's assay portfolio includes sphingotest(R) bio-ADM(R) the assay for bioactive adrenomedullin, a unique biomarker for real-time assessment of vascular integrity in conditions like sepsis or congestive heart failure, sphingotest(R) penKid(R), the assay for proenkephalin, a unique biomarker for real-time assessment of kidney function and sphingotest(R) DPP3, an assay for Dipeptidyl Peptidase 3, a unique biomarker for signaling pathway disruptions leading to acute organ dysfunction. Along with the Nexus IB10 POC platform by its subsidiary Nexus Dx Inc. (San Diego, CA, USA) acquired from Samsung in 2018, sphingotec markets a standard marker portfolio for acute care. In addition, sphingotec developed a portfolio of novel biomarkers, which predict the risks of obesity, breast cancer and cardiovascular diseases.
Contact:
Ruxandra Lenz
PR and Market Communications Manager
+ 49 3302 20565 34
press@sphingotec.de
SOURCE: SphingoTec GmbH
Get a daily dose of Miami Mirror news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Miami Mirror.
More InformationSYDNEY, NSW, Australia - The Australian metropolitan commercial radio audience grew by 2% to nearly 11.1 million listeners in 2020, ...
NEW YORK, New York - According to futures trading, U.S. stocks are likely to sink further when they re-open on ...
WASHINGTON, DC - Tech giant, Apple might finally be getting rid of Touch Bar from its next rendition of the ...
SYDNEY, NSW, Australia - Stocks in mainland China and Hong Kong advanced on Monday on news that the world's second-largest ...
A U.S. businessman, a giant in the pharmaceutical industry, is to be jailed for eighteen years and will have to ...
DUBLIN, Ireland - A major increase in the export of medical and pharmaceutical products has boosted Ireland's balance of trade. ...
KABUL, Afghanistan - Major violence has spread, and escalated across Afghanistan.Scores of national security forces and Taliban militants have been ...
JERUSALEM - Israeli authorities should provide Covid-19 vaccines to the more than 4.5 million Palestinians in the occupied West Bank ...
WASHINGTON, DC - Washington is locked down and U.S. law enforcement officials are geared up for pro-Trump marches in all ...
WASHINGTON, DC - In a sign of the changing political environment in the Middle East, the United States military will ...
WASHINGTON, DC - Outgoing U.S. President Donald Trump's administration carried out its last federal execution when Dustin John Higgs, convicted ...
A Chinese government survey ship was intercepted "running dark" without broadcasting its position via AIS (Automated Identification System) by Indonesian ...